Hals IK, et al. - Whether a type 1 or 2 diabetes-like treatment is best in preserving beta cell function is not established in latent autoimmune diabetes in adults (LADA), researchers assessed the results of glucagon-stimulated C-peptide (GSCT) tests following a 21-month intervention with insulin vs DPP-4 sitagliptin inhibitor. Participants in the study were 64 glutamic acid decarboxylase autoantibody (GADA) positive patients diagnosed with diabetes <3 years prior to the study (aged 30-70 years) and with no clinical need for insulin treatment. In LADA patients treated with insulin and sitagliptin, beta cell function following the intervention was comparable irrespective of the strength of autoimmunity. In addition, in a 21-month perspective, low GADA patients do not experience a progressive deterioration of beta cell function. All these findings should be relevant to the choice of treatment by the clinician in patients with LADA.